Clinical & experimental ophthalmology · 2026
Efficacy and Rebound Effects of Repeated Low-Level Red Light versus High-Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial.
СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xie Jiamin, Zhang Zhihua, Zhang Ting, Xie Dawei, Xu Xun, Lu Yi
Аннотация
BACKGROUND: To compare the efficacy of repeated low-level red light (RLRL) and high-concentration atropine (HCA, 1%) in myopia control and evaluate rebound effects after cessation.
METHODS: In this 15-month, prospective, single-blinded randomized controlled trial, 136 myopic children (6-12 years) were randomly assigned to RLRL or HCA (1:1). Treatment lasted 12 months followed by a 3-month washout. Outcomes included change in axial length (AL), spherical equivalent refraction (SER), subfoveal choroidal thickness (SFChT), and safety.
RESULTS: A total of 116 children completed ≥ 1 follow-up (RLRL: 65, HCA: 51). At 12 months, RLRL showed superior efficacy: AL regressed by -0.014 mm (95% CI: -0.067 to 0.039) versus a 0.094 mm increase with HCA (95% CI: 0.046-0.141; p = 0.005). SER decreased by 0.24 D (95% CI: 0.093-0.387) in RLRL and increased by 0.035 D (95% CI: -0.154 to 0.083) in HCA (p = 0.008), while SFChT increased by 26.000 μm (95% CI: 18.082-33.918) and 12.761 μm (95% CI: 3.867-21.655; p = 0.032), respectively. During the 3-month washout, AL elongation was slightly greater in RLRL (0.163 mm) compared to HCA (0.115 mm; p = 0.014). Higher compliance (≥ 75%) with RLRL correlated with better 12-month efficacy (AL: -0.064 mm vs. 0.084 mm; p = 0.011) but worse rebound (AL: 0.183 mm vs. 0.122 mm; p = 0.02). No severe adverse events were reported.
CONCLUSIONS: RLRL exhibited superior 12-month efficacy over HCA (1%) but was associated with slightly higher rebound. Optimizing RLRL regimens, including implementing reduced dosing and tapered withdrawal, could sustain benefits while limiting rebound.
TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2100051940.
METHODS: In this 15-month, prospective, single-blinded randomized controlled trial, 136 myopic children (6-12 years) were randomly assigned to RLRL or HCA (1:1). Treatment lasted 12 months followed by a 3-month washout. Outcomes included change in axial length (AL), spherical equivalent refraction (SER), subfoveal choroidal thickness (SFChT), and safety.
RESULTS: A total of 116 children completed ≥ 1 follow-up (RLRL: 65, HCA: 51). At 12 months, RLRL showed superior efficacy: AL regressed by -0.014 mm (95% CI: -0.067 to 0.039) versus a 0.094 mm increase with HCA (95% CI: 0.046-0.141; p = 0.005). SER decreased by 0.24 D (95% CI: 0.093-0.387) in RLRL and increased by 0.035 D (95% CI: -0.154 to 0.083) in HCA (p = 0.008), while SFChT increased by 26.000 μm (95% CI: 18.082-33.918) and 12.761 μm (95% CI: 3.867-21.655; p = 0.032), respectively. During the 3-month washout, AL elongation was slightly greater in RLRL (0.163 mm) compared to HCA (0.115 mm; p = 0.014). Higher compliance (≥ 75%) with RLRL correlated with better 12-month efficacy (AL: -0.064 mm vs. 0.084 mm; p = 0.011) but worse rebound (AL: 0.183 mm vs. 0.122 mm; p = 0.02). No severe adverse events were reported.
CONCLUSIONS: RLRL exhibited superior 12-month efficacy over HCA (1%) but was associated with slightly higher rebound. Optimizing RLRL regimens, including implementing reduced dosing and tapered withdrawal, could sustain benefits while limiting rebound.
TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2100051940.